Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study groupDorhout Mees, S. M. & MASH-II study group, Feb-2008, In : International Journal of Stroke. 3, 1, p. 63-5 3 p.
Research output: Contribution to journal › Article › Academic › peer-review
RATIONALE: Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a neuroprotective agent that acts as an NMDA-receptor antagonist and a calcium channel blocker. In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.
AIMS: To determine whether magnesium improves clinical outcome in patients with aneurysmal SAH.
DESIGN: The MASH-II study is a phase III randomized, clinical international multicenter trial. Magnesium sulfate 64 mmol/day (equals 16 g/day) or placebo is started intravenously within 4 days after the SAH and is continued until 20 days after the hemorrhage. The primary outcome measure is poor outcome, defined as death or dependence (Rankin score >3) after 3 months. We aim to include 1200 patients in 5 years.
STUDY OUTCOMES: Primary outcome will be poor clinical outcome as measured by the modified Rankin scale at 3 months.
|Number of pages||3|
|Journal||International Journal of Stroke|
|Publication status||Published - Feb-2008|
- Aneurysm, Ruptured, Anti-Arrhythmia Agents, Humans, Intracranial Aneurysm, Magnesium Sulfate, Subarachnoid Hemorrhage